circle-image

Short

Trend Resistance

Uptrend Above: 23950

Bull Signal Above: 24120
circle-image

Term

Trend Point Acts

Trend Point: 23920

My PCR: 1.04
160 Range 330

Up Trend Signal

circle-image

View

Trend Suport

Down Below: 23890

Bear Signal Below: 23630
Short Term View Historic Data

Nifty View Tomorrow: Thursday 05 Nov 2026

Day Close

23960
Day High

23960
Day Low

23696
Day Avg

23872
04 Nov 2026
5 SMA

23440
10 SMA

23069
20 SMA

22879
50 SMA

23227
200 SMA

24003
5 EMA

23698
10 EMA

23512
20 EMA

23410
50 EMA

23584
Tomorrow
Resist 2

24180
Resist 1

24070
Mid Point

23940
Suport 1

23810
Suport 2

23660
52W High

26373
52w Low

22179
52w Down

9.15%
52w Up

8.03%
Panic View
Resist 2

24400
Resist 1

24235
Mid Point

23910
Suport 1

23585
Suport 2

23360
5d High

23960
5d Low

22656
10d High

23960
10d Low

22372
Days High & Low 20d High

23960
20d Low

22179
50d High

24378
50d Low

22179
All Avg

23206
FFTH

23525
FTTL

22996
TTTH

23431
TTTL

22837
High & Low Avg TTFH

23506
TFFL

22912
High Avg

23487
Low Avg

22915
All Avg

23201
Nifty Historic Prediction Data

Nifty Last Five Days Moves

SNo. Date Day Close Day High Day Low 5 DMA 10 DMA 20 DMA 50 DMA 200 DMA
1 04 Nov 2026 23960 23960 23696 23440 23069 22879 23227 24003
2 03 Nov 2026 23810 23810 23482 23187 22954 22820 23233 24013
3 02 Nov 2026 23440 23440 23214 22975 22862 22757 23242 24022
4 30 Oct 2026 23053 23118 22905 22838 22832 22707 23254 24034
5 29 Oct 2026 22936 22961 22656 22747 22827 22685 23276 24050
Nifty Historic Data And Moving Avg

Go Back

Innova Captab Ltd is an integrated pharmaceutical company in India with a presence across the pha...

Posted: 03 Nov 2024

Innova Captab Ltd is an integrated pharmaceutical company in India with a presence across the pharmaceuticals value chain including research and development, manufacturing, drug distribution and marketing and exports. Since our inception in 2006 with a small base, we have grown strength to strength and for last more than 15 years, we are catering to top Indian pharmaceuticals companies including 10 of the top 10, and 14 of the top 15. We have license to manufacture products through two state of the art manufacturing facilities while maintaining WHO-GMP, EU-GMP and other major registrations. With the support of our world class manufacturing facilities and a reliable supply value chain, we are continuously thriving to maintain highly efficient operations. The foundation of our Company is our in-house research and development (R&D). which helps to focus on to build an increasingly complex product portfolio and attract and retain customers. We proudly possess a strong team of 1000+ employees. As a responsible corporate entity, we are been continuously endeavouring to comply with Environmental, Social & Governance compliance requirements covering the aspects of Legal compliance, ethics & business conduct, quality & patient safety, human rights, labour and employment, health safety and well-being of employees, sustainability & environmental responsibility, quality management system. Our business includes CDMO business providing research, product development and manufacturing services. We were third fastest growing CDMO in terms of Operating Income over the period Fiscal 2019 to Fiscal 2023 and positioned our Company to benefit from the growth in the CDMO market by developing strong R&D and manufacturing operations for our customers to support their domestic sales and exports to certain markets. Fourteen of the top fifteen Indian pharmaceutical companies that CRISIL Research identified as the largest players in the domestic formulation market in Fiscal 2023 have been a part of our customer base. Our Capabilities World class manufacturing facilities in Baddi, Himachal Pradesh and Our manufacturing facilities have good manufacturing practices certifications in conformity with the format recommended by WHO-GMP, EU-GMP and many other international authorities. Strong R&D focus to build an increasingly complex product portfolio and attract and retain customers Our CDMO product portfolio spans across both acute and chronic therapeutic areas Leading presence and one of the fastest growing CDMOs in the Indian pharmaceutical formulations market Well established relationships with our marquee CDMO customer base Our strength in CDMO sphere includes: Our comprehensive CDMO formulation capabilities allow us to offer our customers multiple dosage forms, including oral solids, oral liquids, dry syrups and injectables, as well as more complex delivery forms such as modified and sustained release forms and tablets in capsules. We manufacture products that are in all the top ten therapeutic areas by sales in the Indian formulation market in Fiscal 2023 as identified by CRISIL Research. We manufacture products across some of the key therapeutic areas. Our operational track record in successful delivery of products, R&D, quality and technical standards and productivity Strong R&D and manufacturing operations for our customers to support their domestic sales and exports to certain markets. Our R&D laboratory is equipped with the entire suite of necessary equipment for the development of solid oral and liquid dosage forms Domestic Branded Generics Our Branded Generics business consists of the development, manufacture and distribution of generic formulation products, which are marketed and distributed in India under our own brand names through online and offline channels. Our branded generic products are generic medicines for which the patents have expired, that are sold directly to our distributors, stockists & retailers. We sell our domestic branded generic products through our pan-Indian network of distributors, stockists and pharmacies. Our generic drug products are also available online through various e-commerce pharmacy sites. We have developed a diversified branded generics product portfolio including Tablets, capsules, dry syrups, dry powder injection, ointments and liquid orals

Market Bits

"In investing, what is comfortable is rarely profitable." — Robert Arnott

Be prepared to invest in a down market and to "get out" in a soaring market, as per the philosophy of Warren Buffett.